0000921299false00009212992024-08-302024-08-30

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 30, 2024

 

 

FIBROGEN, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-36740

77-0357827

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

409 Illinois Street

 

San Francisco, California

 

94158

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 415 978-1200

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.01 par value

 

FGEN

 

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

As part of the continuing efforts of FibroGen, Inc. (the “Company”) to implement a significant cost reduction plan in the U.S., which was initiated on August 2, 2024, the Company provided notice of termination to two executive officers on August 30, 2024, each of whom will remain with the Company through a transition period: Juan Graham, Chief Financial Officer and Deyaa Adib, M.D., Chief Medical Officer. Mr. Graham’s planned departure date is December 15, 2024 and Dr. Adib’s planned departure date is November 1, 2024. The Company would like to thank Mr. Graham and Dr. Adib for their service and for the many contributions they made as Chief Financial Officer and Chief Medical Officer, respectively, and as members of the executive team. The employment decisions for Mr. Graham and Dr. Adib are not the result of any disagreement with the Company.

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

FIBROGEN, INC.

 

 

 

 

Date:

September 6, 2024

By:

/s/ Michael Lowenstein

 

 

 

Michael Lowenstein
Chief Legal Officer

 

v3.24.2.u1
Document And Entity Information
Aug. 30, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 30, 2024
Entity Registrant Name FIBROGEN, INC.
Entity Central Index Key 0000921299
Entity Emerging Growth Company false
Entity File Number 001-36740
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 77-0357827
Entity Address, Address Line One 409 Illinois Street
Entity Address, City or Town San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94158
City Area Code 415
Local Phone Number 978-1200
Entity Information, Former Legal or Registered Name  
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.01 par value
Trading Symbol FGEN
Security Exchange Name NASDAQ
FibroGen (NASDAQ:FGEN)
Historical Stock Chart
From Sep 2024 to Oct 2024 Click Here for more FibroGen Charts.
FibroGen (NASDAQ:FGEN)
Historical Stock Chart
From Oct 2023 to Oct 2024 Click Here for more FibroGen Charts.